The role of NF1 loss-of-function in the reactivation of the RAS/MAPK pathway upon BRAF inhibition was confirmed in multiple other melanoma cell lines and in an Nf1-knockout mouse model (Maertens et al., 2013; Nissan et al., 2014). This evidence concerns the gene BRAF and melanoma.